25 XP   0   0   10

Tscan Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Tscan together

PenkeI guess you are interested in Tscan Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Tscan Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Tscan Therapeutics Inc

I send you an email if I find something interesting about Tscan Therapeutics Inc.

Quick analysis of Tscan (30 sec.)










What can you expect buying and holding a share of Tscan? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
6.3%

What is your share worth?

Current worth
$1.59
Expected worth in 1 year
$0.90
How sure are you?
18.8%

+ What do you gain per year?

Total Gains per Share
$-0.69
Return On Investment
-8.7%

For what price can you sell your share?

Current Price per Share
$7.94
Expected price per share
$6.4 - $
How sure are you?
50%

1. Valuation of Tscan (5 min.)




Live pricePrice per Share (EOD)

$7.94

Intrinsic Value Per Share

$-13.07 - $-15.14

Total Value Per Share

$-11.48 - $-13.55

2. Growth of Tscan (5 min.)




Is Tscan growing?

Current yearPrevious yearGrowGrow %
How rich?$150.8m$123.3m$23.7m16.1%

How much money is Tscan making?

Current yearPrevious yearGrowGrow %
Making money-$22.4m-$16.4m-$6m-26.9%
Net Profit Margin-492.6%-470,269.1%--

How much money comes from the company's main activities?

3. Financial Health of Tscan (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#313 / 1031

Most Revenue
#342 / 1031

Most Profit
#756 / 1031

Most Efficient
#757 / 1031

What can you expect buying and holding a share of Tscan? (5 min.)

Welcome investor! Tscan's management wants to use your money to grow the business. In return you get a share of Tscan.

What can you expect buying and holding a share of Tscan?

First you should know what it really means to hold a share of Tscan. And how you can make/lose money.

Speculation

The Price per Share of Tscan is $7.94. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Tscan.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Tscan, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.59. Based on the TTM, the Book Value Change Per Share is $-0.17 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.35 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Tscan.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.21-2.6%-0.37-4.6%-0.38-4.8%-0.29-3.7%-0.29-3.7%
Usd Book Value Change Per Share-0.19-2.4%-0.17-2.2%-0.35-4.4%0.101.3%0.101.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.19-2.4%-0.17-2.2%-0.35-4.4%0.101.3%0.101.3%
Usd Price Per Share5.83-3.25-2.64-2.27-2.27-
Price to Earnings Ratio-7.05--2.98--1.78--1.76--1.76-
Price-to-Total Gains Ratio-30.54--8.71--7.66--7.87--7.87-
Price to Book Ratio3.66-1.72-0.92-0.87-0.87-
Price-to-Total Gains Ratio-30.54--8.71--7.66--7.87--7.87-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share7.94
Number of shares125
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.170.10
Usd Total Gains Per Share-0.170.10
Gains per Quarter (125 shares)-21.5512.48
Gains per Year (125 shares)-86.1849.93
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-86-9605040
20-172-18209990
30-259-2681149140
40-345-3541199190
50-431-4401249240
60-517-5261298290
70-603-6122348340
80-689-6982398390
90-776-7842447440
100-862-8702497490

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.016.00.00.0%0.016.00.00.0%0.016.00.00.0%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%3.011.02.018.8%3.011.02.018.8%3.011.02.018.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%1.00.015.06.3%1.00.015.06.3%1.00.015.06.3%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%3.011.02.018.8%3.011.02.018.8%3.011.02.018.8%

Fundamentals of Tscan

About Tscan Therapeutics Inc

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors. The company also developing TSC-200, TSC-201, TSC-202, TSC-203, and TSC-205 for the treatment of solid tumors. In addition, it engages in the developing vaccines for infectious diseases, such as SARS-CoV-2. The company has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer; and a collaboration agreement with Amgen to identify novel targets in Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Fundamental data was last updated by Penke on 2024-03-09 19:38:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Tscan Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Tscan earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Tscan to the Biotechnology industry mean.
  • A Net Profit Margin of -272.0% means that $-2.72 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Tscan Therapeutics Inc:

  • The MRQ is -272.0%. The company is making a huge loss. -2
  • The TTM is -492.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-272.0%TTM-492.6%+220.6%
TTM-492.6%YOY-470,269.1%+469,776.4%
TTM-492.6%5Y-118,026.9%+117,534.3%
5Y-118,026.9%10Y-118,026.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-272.0%-159.2%-112.8%
TTM-492.6%-202.3%-290.3%
YOY-470,269.1%-263.0%-470,006.1%
5Y-118,026.9%-452.4%-117,574.5%
10Y-118,026.9%-589.0%-117,437.9%
1.1.2. Return on Assets

Shows how efficient Tscan is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Tscan to the Biotechnology industry mean.
  • -7.2% Return on Assets means that Tscan generated $-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Tscan Therapeutics Inc:

  • The MRQ is -7.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.2%TTM-9.0%+1.8%
TTM-9.0%YOY-9.6%+0.6%
TTM-9.0%5Y-7.8%-1.2%
5Y-7.8%10Y-7.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.2%-12.5%+5.3%
TTM-9.0%-12.2%+3.2%
YOY-9.6%-11.2%+1.6%
5Y-7.8%-13.3%+5.5%
10Y-7.8%-14.6%+6.8%
1.1.3. Return on Equity

Shows how efficient Tscan is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Tscan to the Biotechnology industry mean.
  • -13.0% Return on Equity means Tscan generated $-0.13 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Tscan Therapeutics Inc:

  • The MRQ is -13.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -17.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.0%TTM-17.3%+4.3%
TTM-17.3%YOY-13.7%-3.5%
TTM-17.3%5Y-9.6%-7.7%
5Y-9.6%10Y-9.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.0%-16.0%+3.0%
TTM-17.3%-15.8%-1.5%
YOY-13.7%-13.9%+0.2%
5Y-9.6%-18.2%+8.6%
10Y-9.6%-19.1%+9.5%

1.2. Operating Efficiency of Tscan Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Tscan is operating .

  • Measures how much profit Tscan makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Tscan to the Biotechnology industry mean.
  • An Operating Margin of -296.2% means the company generated $-2.96  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Tscan Therapeutics Inc:

  • The MRQ is -296.2%. The company is operating very inefficient. -2
  • The TTM is -508.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-296.2%TTM-508.3%+212.1%
TTM-508.3%YOY-466,550.8%+466,042.5%
TTM-508.3%5Y-117,101.4%+116,593.0%
5Y-117,101.4%10Y-117,101.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-296.2%-299.5%+3.3%
TTM-508.3%-208.5%-299.8%
YOY-466,550.8%-280.2%-466,270.6%
5Y-117,101.4%-459.9%-116,641.5%
10Y-117,101.4%-596.9%-116,504.5%
1.2.2. Operating Ratio

Measures how efficient Tscan is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3.96 means that the operating costs are $3.96 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Tscan Therapeutics Inc:

  • The MRQ is 3.962. The company is inefficient in keeping operating costs low. -1
  • The TTM is 6.363. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.962TTM6.363-2.401
TTM6.363YOY5,811.353-5,804.990
TTM6.3635Y1,458.210-1,451.846
5Y1,458.21010Y1,458.2100.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.9622.817+1.145
TTM6.3633.181+3.182
YOY5,811.3533.609+5,807.744
5Y1,458.2105.554+1,452.656
10Y1,458.2107.396+1,450.814

1.3. Liquidity of Tscan Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Tscan is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.51 means the company has $6.51 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Tscan Therapeutics Inc:

  • The MRQ is 6.514. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.987. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.514TTM5.987+0.527
TTM5.987YOY7.718-1.731
TTM5.9875Y5.309+0.678
5Y5.30910Y5.3090.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.5143.987+2.527
TTM5.9874.440+1.547
YOY7.7185.569+2.149
5Y5.3096.158-0.849
10Y5.3096.492-1.183
1.3.2. Quick Ratio

Measures if Tscan is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Tscan to the Biotechnology industry mean.
  • A Quick Ratio of 8.41 means the company can pay off $8.41 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Tscan Therapeutics Inc:

  • The MRQ is 8.408. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 7.142. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ8.408TTM7.142+1.266
TTM7.142YOY7.538-0.396
TTM7.1425Y5.504+1.638
5Y5.50410Y5.5040.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.4083.653+4.755
TTM7.1424.158+2.984
YOY7.5385.515+2.023
5Y5.5046.012-0.508
10Y5.5046.206-0.702

1.4. Solvency of Tscan Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Tscan assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Tscan to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.45 means that Tscan assets are financed with 44.6% credit (debt) and the remaining percentage (100% - 44.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Tscan Therapeutics Inc:

  • The MRQ is 0.446. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.454. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.446TTM0.454-0.008
TTM0.454YOY0.266+0.187
TTM0.4545Y0.595-0.142
5Y0.59510Y0.5950.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4460.336+0.110
TTM0.4540.330+0.124
YOY0.2660.267-0.001
5Y0.5950.367+0.228
10Y0.5950.378+0.217
1.4.2. Debt to Equity Ratio

Measures if Tscan is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Tscan to the Biotechnology industry mean.
  • A Debt to Equity ratio of 80.4% means that company has $0.80 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Tscan Therapeutics Inc:

  • The MRQ is 0.804. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.854. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.804TTM0.854-0.050
TTM0.854YOY0.433+0.421
TTM0.8545Y0.582+0.272
5Y0.58210Y0.5820.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8040.376+0.428
TTM0.8540.398+0.456
YOY0.4330.334+0.099
5Y0.5820.431+0.151
10Y0.5820.476+0.106

2. Market Valuation of Tscan Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Tscan generates.

  • Above 15 is considered overpriced but always compare Tscan to the Biotechnology industry mean.
  • A PE ratio of -7.05 means the investor is paying $-7.05 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Tscan Therapeutics Inc:

  • The EOD is -9.598. Based on the earnings, the company is expensive. -2
  • The MRQ is -7.048. Based on the earnings, the company is expensive. -2
  • The TTM is -2.982. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.598MRQ-7.048-2.551
MRQ-7.048TTM-2.982-4.065
TTM-2.982YOY-1.777-1.205
TTM-2.9825Y-1.765-1.218
5Y-1.76510Y-1.7650.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-9.598-2.697-6.901
MRQ-7.048-2.422-4.626
TTM-2.982-2.709-0.273
YOY-1.777-4.116+2.339
5Y-1.765-6.257+4.492
10Y-1.765-6.478+4.713
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Tscan Therapeutics Inc:

  • The EOD is -7.768. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.703. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 0.311. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-7.768MRQ-5.703-2.064
MRQ-5.703TTM0.311-6.014
TTM0.311YOY-1.651+1.962
TTM0.3115Y-0.912+1.223
5Y-0.91210Y-0.9120.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.768-3.344-4.424
MRQ-5.703-2.939-2.764
TTM0.311-3.486+3.797
YOY-1.651-5.592+3.941
5Y-0.912-8.464+7.552
10Y-0.912-8.872+7.960
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Tscan is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.66 means the investor is paying $3.66 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Tscan Therapeutics Inc:

  • The EOD is 4.991. Based on the equity, the company is fair priced.
  • The MRQ is 3.665. Based on the equity, the company is fair priced.
  • The TTM is 1.724. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD4.991MRQ3.665+1.326
MRQ3.665TTM1.724+1.941
TTM1.724YOY0.925+0.799
TTM1.7245Y0.869+0.855
5Y0.86910Y0.8690.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.9912.198+2.793
MRQ3.6652.042+1.623
TTM1.7242.121-0.397
YOY0.9252.907-1.982
5Y0.8693.682-2.813
10Y0.8694.114-3.245
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Tscan Therapeutics Inc.

3.1. Institutions holding Tscan Therapeutics Inc

Institutions are holding 83.235% of the shares of Tscan Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30EcoR1 Capital, LLC10.45490.4318500000000
2023-12-31Adage Capital Partners Gp LLC8.15480.04713900000-100000-2.5
2023-09-30Bvf Inc6.25090.2064298947400
2023-09-30Baker Bros Advisors LP5.82290.0411278479200
2023-09-30Vanguard Group Inc3.66460.0001175259439330528.9346
2023-12-31BlackRock Inc3.49550.00031671727-8722-0.519
2023-09-30Alphabet Inc2.25210.1771107708000
2023-09-30Simplify Asset Management Inc.2.18910.3064104691600
2023-09-30DC Funds, LP1.317333.199663000000
2023-09-30Geode Capital Management, LLC0.64390.0001307938191047163.4403
2023-09-30Morgan Stanley - Brokerage Accounts0.54250.0001259447150972139.1768
2023-12-31Stifel Financial Corp0.25180.000912040035002.994
2023-12-31Marshall Wace Asset Management Ltd0.23120.00111105511105510
2023-09-30NewEdge Wealth, LLC0.19120.00749146300
2023-12-31Bridgeway Capital Management, LLC0.18460.0118830000
2023-09-30Northern Trust Corp0.150507197656921378.087
2023-12-31Man Group PLC0.10540.000850410504100
2023-12-31Balyasny Asset Management LLC0.09620.000545986459860
2023-12-31683 Capital Management LLC0.09030.020643198431980
2023-09-30State Street Corporation0.087204170032008.3117
Total 46.176934.452422083952+940368+4.3%

3.2. Funds holding Tscan Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Vanguard Total Stock Mkt Idx Inv2.49020.0004119093400
2024-01-31Simplify Propel Opportunities ETF2.18915.7174104691600
2024-01-31BlackRock Health Sciences Term Trust2.18670.2837104576700
2024-01-31Vanguard Institutional Extnd Mkt Idx Tr1.12450.002953779326000.4858
2023-12-31Fidelity Extended Market Index0.45280.003521656675043.5894
2024-01-31abrdn Healthcare Investors0.28870.070213805700
2023-12-31BlackRock Extended Equity Market K0.18840.0038900852225532.81
2023-09-30Bridgeway Ultra-Small Company Market0.18460.1346883003830076.6
2023-09-30BlackRock Extended Mkt Composite0.16220.001477593775930
2024-01-31abrdn Life Sciences Investors0.12950.07126194300
2023-12-31Fidelity Total Market Index0.12680.00046066030900103.8306
2024-02-28iShares Micro-Cap ETF0.12170.0432581803780.654
2023-12-31Fidelity Series Total Market Index0.10480.00055012900
2023-12-31NT Ext Equity Mkt Idx Fd - L0.07350.0035351578132.3672
2023-12-31Northern Trust Extended Eq Market Idx0.07350.0035351578132.3672
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.07190.000534364-186570-84.446
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.06950.00313322200
2023-12-31LUNIS Biotech Growth Opp Fd I a0.06696.64373200000
2024-02-28Avantis US Small Cap Equity ETF0.06120.02382926600
2023-12-31Fidelity Nasdaq Composite Index0.05710.00112730300
Total 10.223613.01244889392-5414-0.1%

3.3. Insider Transactions

Insiders are holding 0.821% of the shares of Tscan Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-12-18Timothy J BarberichBUY288304.89
2023-12-14Barbara KlenckeBUY50005.08
2023-06-02Timothy J BarberichBUY378802.63
2023-05-31Lynx1 Capital Management LpSELL254002.52

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Tscan Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.191-0.172-10%-0.352+84%0.099-292%0.099-292%
Book Value Per Share--1.5912.300-31%2.829-44%2.210-28%2.210-28%
Current Ratio--6.5145.987+9%7.718-16%5.309+23%5.309+23%
Debt To Asset Ratio--0.4460.454-2%0.266+67%0.595-25%0.595-25%
Debt To Equity Ratio--0.8040.854-6%0.433+86%0.582+38%0.582+38%
Dividend Per Share----0%-0%0.000-100%0.000-100%
Eps---0.207-0.369+78%-0.380+84%-0.294+42%-0.294+42%
Free Cash Flow Per Share---0.256-0.305+19%-0.405+59%-0.272+6%-0.272+6%
Free Cash Flow To Equity Per Share---0.2551.190-121%-0.237-7%0.416-161%0.416-161%
Gross Profit Margin--1.0651.016+5%1.000+7%1.004+6%1.004+6%
Intrinsic Value_10Y_max---15.140--------
Intrinsic Value_10Y_min---13.075--------
Intrinsic Value_1Y_max---1.415--------
Intrinsic Value_1Y_min---1.390--------
Intrinsic Value_3Y_max---4.330--------
Intrinsic Value_3Y_min---4.132--------
Intrinsic Value_5Y_max---7.339--------
Intrinsic Value_5Y_min---6.805--------
Market Cap346228464.000-60%552892335.050251312538.923+120%114955263.000+381%126560444.481+337%126560444.481+337%
Net Profit Margin---2.720-4.926+81%-4702.691+172801%-1180.269+43294%-1180.269+43294%
Operating Margin---2.962-5.083+72%-4665.508+157427%-1171.014+39438%-1171.014+39438%
Operating Ratio--3.9626.363-38%5811.353-100%1458.210-100%1458.210-100%
Pb Ratio4.991+27%3.6651.724+113%0.925+296%0.869+322%0.869+322%
Pe Ratio-9.598-36%-7.048-2.982-58%-1.777-75%-1.765-75%-1.765-75%
Price Per Share7.940+27%5.8303.248+80%2.636+121%2.273+156%2.273+156%
Price To Free Cash Flow Ratio-7.768-36%-5.7030.311-1935%-1.651-71%-0.912-84%-0.912-84%
Price To Total Gains Ratio-41.592-36%-30.539-8.709-71%-7.664-75%-7.870-74%-7.870-74%
Quick Ratio--8.4087.142+18%7.538+12%5.504+53%5.504+53%
Return On Assets---0.072-0.090+25%-0.096+33%-0.078+8%-0.078+8%
Return On Equity---0.130-0.173+33%-0.137+6%-0.096-26%-0.096-26%
Total Gains Per Share---0.191-0.172-10%-0.352+84%0.100-291%0.100-291%
Usd Book Value--150867000.000147113250.000+3%123359500.000+22%108065250.000+40%108065250.000+40%
Usd Book Value Change Per Share---0.191-0.172-10%-0.352+84%0.099-292%0.099-292%
Usd Book Value Per Share--1.5912.300-31%2.829-44%2.210-28%2.210-28%
Usd Dividend Per Share----0%-0%0.000-100%0.000-100%
Usd Eps---0.207-0.369+78%-0.380+84%-0.294+42%-0.294+42%
Usd Free Cash Flow---24235000.000-16126000.000-33%-17682000.000-27%-12569437.500-48%-12569437.500-48%
Usd Free Cash Flow Per Share---0.256-0.305+19%-0.405+59%-0.272+6%-0.272+6%
Usd Free Cash Flow To Equity Per Share---0.2551.190-121%-0.237-7%0.416-161%0.416-161%
Usd Market Cap346228464.000-60%552892335.050251312538.923+120%114955263.000+381%126560444.481+337%126560444.481+337%
Usd Price Per Share7.940+27%5.8303.248+80%2.636+121%2.273+156%2.273+156%
Usd Profit---19613000.000-22498500.000+15%-16451500.000-16%-14409500.000-27%-14409500.000-27%
Usd Revenue--7211000.0005262250.000+37%2610250.000+176%6272187.500+15%6272187.500+15%
Usd Total Gains Per Share---0.191-0.172-10%-0.352+84%0.100-291%0.100-291%
 EOD+3 -5MRQTTM+22 -12YOY+22 -125Y+19 -1710Y+19 -17

4.2. Fundamental Score

Let's check the fundamental score of Tscan Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-9.598
Price to Book Ratio (EOD)Between0-14.991
Net Profit Margin (MRQ)Greater than0-2.720
Operating Margin (MRQ)Greater than0-2.962
Quick Ratio (MRQ)Greater than18.408
Current Ratio (MRQ)Greater than16.514
Debt to Asset Ratio (MRQ)Less than10.446
Debt to Equity Ratio (MRQ)Less than10.804
Return on Equity (MRQ)Greater than0.15-0.130
Return on Assets (MRQ)Greater than0.05-0.072
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Tscan Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5064.045
Ma 20Greater thanMa 507.207
Ma 50Greater thanMa 1006.387
Ma 100Greater thanMa 2005.913
OpenGreater thanClose8.270
Total5/5 (100.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets272,149
Total Liabilities121,282
Total Stockholder Equity150,867
 As reported
Total Liabilities 121,282
Total Stockholder Equity+ 150,867
Total Assets = 272,149

Assets

Total Assets272,149
Total Current Assets194,237
Long-term Assets77,912
Total Current Assets
Cash And Cash Equivalents 133,359
Short-term Investments 58,685
Other Current Assets 2,193
Total Current Assets  (as reported)194,237
Total Current Assets  (calculated)194,237
+/-0
Long-term Assets
Property Plant Equipment 71,234
Long-term Assets Other 1,647
Long-term Assets  (as reported)77,912
Long-term Assets  (calculated)72,881
+/- 5,031

Liabilities & Shareholders' Equity

Total Current Liabilities29,820
Long-term Liabilities91,462
Total Stockholder Equity150,867
Total Current Liabilities
Short-term Debt 6,593
Short Long Term Debt 3,347
Accounts payable 2,374
Other Current Liabilities 10,716
Total Current Liabilities  (as reported)29,820
Total Current Liabilities  (calculated)23,030
+/- 6,790
Long-term Liabilities
Long term Debt 26,700
Capital Lease Obligations 62,386
Long-term Liabilities  (as reported)91,462
Long-term Liabilities  (calculated)89,086
+/- 2,376
Total Stockholder Equity
Common Stock5
Retained Earnings -247,597
Other Stockholders Equity 398,459
Total Stockholder Equity (as reported)150,867
Total Stockholder Equity (calculated)150,867
+/-0
Other
Capital Stock5
Cash and Short Term Investments 192,044
Common Stock Shares Outstanding 94,836
Current Deferred Revenue10,137
Liabilities and Stockholders Equity 272,149
Net Debt -40,926
Net Invested Capital 180,914
Net Working Capital 164,417
Property Plant and Equipment Gross 85,831
Short Long Term Debt Total 92,433



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
> Total Assets 
411,898
351,784
0
0
49,738
140,940
130,007
204,889
188,107
168,204
152,415
165,454
199,091
173,577
316,923
291,379
272,149
272,149291,379316,923173,577199,091165,454152,415168,204188,107204,889130,007140,94049,73800351,784411,898
   > Total Current Assets 
5,890
22,076
0
0
36,445
123,873
110,070
187,003
165,654
145,749
129,360
141,177
120,027
95,608
208,842
155,193
194,237
194,237155,193208,84295,608120,027141,177129,360145,749165,654187,003110,070123,87336,4450022,0765,890
       Cash And Cash Equivalents 
5,890
22,076
0
0
34,791
121,501
106,197
182,312
161,405
140,838
125,603
137,306
120,027
95,608
208,842
155,193
133,359
133,359155,193208,84295,608120,027137,306125,603140,838161,405182,312106,197121,50134,7910022,0765,890
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
60,230
58,685
58,68560,230000000000000000
       Net Receivables 
0
4,316
0
0
0
0
0
0
0
0
0
0
0
0
31,926
0
0
0031,9260000000000004,3160
       Other Current Assets 
0
-4,316
0
0
1,654
2,372
3,873
4,691
4,249
4,911
3,757
3,871
4,100
5,299
1,450
2,144
2,193
2,1932,1441,4505,2994,1003,8713,7574,9114,2494,6913,8732,3721,65400-4,3160
   > Long-term Assets 
0
2,315
0
0
13,293
17,067
19,937
17,886
22,453
22,455
23,055
24,277
79,064
77,969
108,081
136,186
77,912
77,912136,186108,08177,96979,06424,27723,05522,45522,45317,88619,93717,06713,293002,3150
       Property Plant Equipment 
0
0
0
0
12,532
15,183
16,636
17,125
17,256
15,814
15,553
14,702
69,202
66,933
68,027
67,134
71,234
71,23467,13468,02766,93369,20214,70215,55315,81417,25617,12516,63615,18312,5320000
       Long-term Assets Other 
0
-2,315
0
0
761
1,884
3,301
761
5,197
6,641
7,502
4,538
4,825
6,005
35,023
64,021
1,647
1,64764,02135,0236,0054,8254,5387,5026,6415,1977613,3011,88476100-2,3150
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
2,540
0
0
0
0
0
0
0
0
0
0
00000000002,540000000
> Total Liabilities 
182,443
196,879
0
0
92,200
190,862
190,037
30,815
27,329
22,510
20,763
48,796
99,657
95,559
126,316
122,418
121,282
121,282122,418126,31695,55999,65748,79620,76322,51027,32930,815190,037190,86292,20000196,879182,443
   > Total Current Liabilities 
108,866
109,067
0
0
17,446
18,838
20,617
22,944
21,343
18,465
17,170
16,594
17,305
14,047
35,118
33,151
29,820
29,82033,15135,11814,04717,30516,59417,17018,46521,34322,94420,61718,83817,44600109,067108,866
       Short-term Debt 
108,866
109,067
0
0
1,415
1,530
1,575
1,620
1,651
1,698
1,746
1,795
3,681
3,836
4,209
5,486
6,593
6,5935,4864,2093,8363,6811,7951,7461,6981,6511,6201,5751,5301,41500109,067108,866
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,110
3,347
3,3471,110000000000000000
       Accounts payable 
0
0
0
0
2,910
3,574
3,547
5,072
1,765
2,886
3,096
2,708
2,912
2,773
3,394
3,196
2,374
2,3743,1963,3942,7732,9122,7083,0962,8861,7655,0723,5473,5742,9100000
       Other Current Liabilities 
0
0
0
0
2,494
2,352
3,749
4,285
6,517
3,012
4,158
6,159
6,838
7,438
8,304
9,257
10,716
10,7169,2578,3047,4386,8386,1594,1583,0126,5174,2853,7492,3522,4940000
   > Long-term Liabilities 
108,866
109,067
0
0
74,754
172,024
169,420
7,871
5,986
4,045
3,593
32,202
82,352
81,512
91,198
89,267
91,462
91,46289,26791,19881,51282,35232,2023,5934,0455,9867,871169,420172,02474,75400109,067108,866
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
2,540
0
0
0
0
0
0
0
0
0
0
00000000002,540000000
       Warrants
0
0
0
0
0
0
159,411
0
0
0
0
0
0
0
0
0
0
0000000000159,411000000
       Other Liabilities 
0
0
0
0
0
6,994
4,798
3,080
1,594
97
20,763
97
49
0
7,668
0
0
007,6680499720,763971,5943,0804,7986,99400000
       Deferred Long Term Liability 
0
0
0
0
0
1,123
2,540
0
0
0
0
0
0
0
0
0
0
00000000002,5401,12300000
> Total Stockholder Equity
30
154,905
0
0
-42,462
-49,922
-60,030
174,074
160,778
145,694
131,652
116,658
99,434
78,018
190,607
168,961
150,867
150,867168,961190,60778,01899,434116,658131,652145,694160,778174,074-60,030-49,922-42,46200154,90530
   Common Stock
30
30
0
0
1
1
1
3
3
3
3
3
3
3
5
5
5
5553333333111003030
   Retained Earnings -247,597-227,984-204,987-180,942-158,379-139,656-123,411-108,314-92,158-77,958-62,119-51,445-43,5330000
   Accumulated Other Comprehensive Income 000000000-204,889-159,411000000
   Capital Surplus 
0
0
0
0
0
0
2,088
252,029
252,933
0
255,060
256,311
257,810
258,957
0
0
0
000258,957257,810256,311255,0600252,933252,0292,088000000
   Treasury Stock00000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue21,049
Cost of Revenue-5,361
Gross Profit15,68815,688
 
Operating Income (+$)
Gross Profit15,688
Operating Expense-109,146
Operating Income-93,458-93,458
 
Operating Expense (+$)
Research Development88,153
Selling General Administrative26,354
Selling And Marketing Expenses5,361
Operating Expense109,146119,868
 
Net Interest Income (+$)
Interest Income6,304
Interest Expense-3,759
Other Finance Cost-123
Net Interest Income2,422
 
Pretax Income (+$)
Operating Income-93,458
Net Interest Income2,422
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-89,218-97,698
EBIT - interestExpense = -97,217
-89,218
-85,459
Interest Expense3,759
Earnings Before Interest and Taxes (EBIT)-93,458-85,459
Earnings Before Interest and Taxes (EBITDA)-88,097
 
After tax Income (+$)
Income Before Tax-89,218
Tax Provision-0
Net Income From Continuing Ops-88,328-89,218
Net Income-89,218
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses114,507
Total Other Income/Expenses Net4,240-2,422
 

Technical Analysis of Tscan
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Tscan. The general trend of Tscan is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Tscan's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Tscan Therapeutics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: .

The bearish price targets are: 7.87 > 7.67 > 6.4.

Tweet this
Tscan Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Tscan Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Tscan Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Tscan Therapeutics Inc. The current macd is 0.42268922.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Tscan price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Tscan. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Tscan price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Tscan Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartTscan Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Tscan Therapeutics Inc. The current adx is 32.70.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Tscan shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Tscan Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Tscan Therapeutics Inc. The current sar is 6.73360469.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Tscan Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Tscan Therapeutics Inc. The current rsi is 64.04. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Tscan Therapeutics Inc Daily Relative Strength Index (RSI) ChartTscan Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Tscan Therapeutics Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Tscan price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Tscan Therapeutics Inc Daily Stochastic Oscillator ChartTscan Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Tscan Therapeutics Inc. The current cci is 103.85.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Tscan Therapeutics Inc Daily Commodity Channel Index (CCI) ChartTscan Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Tscan Therapeutics Inc. The current cmo is 29.59.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Tscan Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartTscan Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Tscan Therapeutics Inc. The current willr is -41.08527132.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Tscan is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Tscan Therapeutics Inc Daily Williams %R ChartTscan Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Tscan Therapeutics Inc.

Tscan Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Tscan Therapeutics Inc. The current atr is 0.60757647.

Tscan Therapeutics Inc Daily Average True Range (ATR) ChartTscan Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Tscan Therapeutics Inc. The current obv is 67,305,204.

Tscan Therapeutics Inc Daily On-Balance Volume (OBV) ChartTscan Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Tscan Therapeutics Inc. The current mfi is 68.49.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Tscan Therapeutics Inc Daily Money Flow Index (MFI) ChartTscan Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Tscan Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-09STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-14BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-16MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-24CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-30ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-23BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-25RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside

6.3. Candlestick Patterns

Tscan Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Tscan Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5064.045
Ma 20Greater thanMa 507.207
Ma 50Greater thanMa 1006.387
Ma 100Greater thanMa 2005.913
OpenGreater thanClose8.270
Total5/5 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Tscan with someone you think should read this too:
  • Are you bullish or bearish on Tscan? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Tscan? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Tscan Therapeutics Inc

I send you an email if I find something interesting about Tscan Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Tscan Therapeutics Inc.

Receive notifications about Tscan Therapeutics Inc in your mailbox!